| Name | Title | Contact Details |
|---|
In 2007 the Delaware Health Information Network (DHIN) became the first live, statewide health information network in the nation. DHIN currently serves: - 100% of Delaware’s acute care hospitals - 100% of Delaware’s long term care and skilled nursing facilities - Approaching 100% of medical providers who have enrolled and are participating in DHIN More than 14,000,000 clinical results and reports are posted on DHIN each year – and the total patient records in the system now exceed 2,100,000, featuring patient records from all 50 states. In the six years that DHIN has been active, the system has proven its reliability and worth to hospitals, medical professionals and patients throughout Delaware. DHIN securely delivers fast and accurate patient information from hospitals, laboratories, and radiology facilities directly to doctors’ offices. DHIN makes it possible to deliver higher quality medical care more quickly, and at a lower cost, using a federated data model for medical records, aggregating those records and eliminating the manual transmittal of medical data. Frequent audits confirm that the system is secure and that data is used properly. The Delaware Health Information Network (DHIN) was enacted by the Delaware General Assembly in 1997 as a public-private partnership for the benefit of all citizens of Delaware to advance the creation of a statewide health information network and to address Delaware`s needs for timely, reliable and relevant health care information.
AMAR INTERNATIONAL is a Fairfax, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Physicians Immediate Care is a Richland, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Northwestern Community Services Board is a public mental health provider that offers an array of outpatient, case management, day support, residential and emergency programs that are designed to enhance the quality of life for both children and adults ...
MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.